Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.
  • TickerONXEO
  • ISINFR0010095596
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Onxeo - First Phase Ib DRIIV results released

On 18 September 2019, Onxeo released initial results from the first cohort of patients (n=3) in its ongoing Phase Ib DRIIV study with AsiDNA. The three patients had a progressive metastatic cancer (non-small cell lung cancer, triple negative breast cancer, gastric cancer) and were treated with AsiDNA plus carboplatin. No dose-limiting toxicity was observed. Two of the three patients have shown stable disease (RECIST) since the start of the treatment (more than four and five months). While it is too early to draw any conclusions on efficacy, stable disease status in 2/3 patients and a good safe...

Onxeo - Next generation of DNA damage repair inhibitors

Onxeo is focused on the development of the next generation of DNA damage repair inhibitors from its novel oligonucleotide platON platform. The lead asset, AsiDNA, belongs to the same class of drugs as PARP inhibitors, but has a different mechanism of action. AsiDNA is in a Phase Ib trial in combination with chemotherapy in solid tumours; preliminary results are expected by end-2019, which is within the existing cash reach to Q320. To reflect the progress Onxeo has made with AsiDNA we have included the second indication for this asset in our valuation, but removed some of the legacy projects. O...

Dr Jonas Peciulis

Onxeo - Green light for Ph Ib/II after DRIIV-1 interim data

Onxeo’s lead asset, AsiDNA, is currently being tested in a Phase I DRIIV-1 trial in patients with advanced solid tumours (n=36). Interim results were announced recently, based on which Onxeo will initiate a further Phase Ib/II development programme, likely combining AsiDNA with other standard-of-care drugs that have shown the highest potential in preclinical models. The most interesting combination seems to be with PARP inhibitors. These activities are being funded by cash raised from the recent Beleodaq royalty stream monetisation ($7.5m) and equity financing agreement, both in June 2018. Our...

Dr Jonas Peciulis

Onxeo - Phase I with AsiDNA iv starts; first data in H218

On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via systemic administration in the Phase I trial. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection. Alongside the Phase I trial Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. Two abstracts with preclinical data were presented at the American Association for Cancer Research conference in April potentially demonstrating unique characte...

Dr Jonas Peciulis

Onxeo - Introducing platON; AsiDNA approaches Phase I

Onxeo has experienced a volatile 2017 mainly due to Livatag’s Phase III ReLive not meeting its primary endpoint. The out-licensing of Validive, fresh data from several preclinical studies with core assets – AsiDNA and belinostat combinations – were more positive recent developments. Although the share price halved after the disappointing ReLive data, the asset portfolio has been radically reshaped to focus on DNA break repair inhibition and epigenetics and Onxeo has cash reach until 2020. Our updated valuation is €218m (vs €350m) or €4.3/share.

1 director bought

A director at Onxeo bought 300,000 shares at 1.199EUR and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board member...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Florian Béchaz

Onxeo - Assemblée Générale des actionnaires du 26 avril 2019

Si les rémunérations 2018 de Mme Gréciet, Directrice Générale, présentent des montants plutôt acceptables, le problème de sa rémunération demeure que sa rémunération sous forme d'options et d'actions de performance est assortie de conditions de performance court-termistes.Non seulement cela ne répond pas aux préconisations de Proxinvest et des investisseurs, mais cela demeure plutôt étonnant de la part d'une biotech. En effet, ces sociétés biopharmaceutiques ont un business-model qui repose lui-même sur le très long-terme ; il semblerait donc tout à fait cohérent que les rémunérations long-ter...

Jehanne Leroy

Proxy Report - 16/05/2018

Si les rémunérations 2017 de Mme Gréciet, Directrice Générale, présentent des montants plutôt acceptables, le réel problème de sa rémunération demeure que sa rémunération sous forme d'options et d'actions de performance est assortie de conditions de performance court-termistes. Non seulement cela ne répond pas aux préconisations de Proxinvest et des investisseurs, mais cela demeure plutôt étonnant de la part d'une biotech. En effet, ces sociétés biopharmaceutiques ont un business-model qui repose lui-même sur le très long-terme ; il semblerait donc tout à fait cohérent que les rémunérations l...

Jehanne Leroy

Etude de l'AG du 26/04/2017

La société se référant au code MiddleNext, les actionnaires ont, en vertu de la Loi Sapin 2, pour la première fois l'occasion de se prononcer sur les rémunérations des dirigeants.Si les rémunérations de Mme Gréciet, Directrice Générale, présentent des montants plutôt acceptables, le réel problème de sa rémunération demeure que sa rémunération sous forme d'options et d'actions de performance est assortie de conditions de performance court-termiste.Non seulement cela ne répond pas aux préconisations de Proxinvest et des investisseurs, mais cela demeure plutôt étonnant de la part d'une biotech. E...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch